Compass Therapeutics, Inc.
CMPX
$1.97
$0.105.35%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 40.66% | 22.12% | -17.54% | -1.48% | 51.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.99% | 8.54% | 29.23% | 32.53% | 40.69% |
| Operating Income | -12.99% | -8.54% | -29.23% | -40.02% | -40.69% |
| Income Before Tax | -10.12% | -4.54% | -36.05% | -52.04% | -54.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.12% | -4.54% | -36.05% | -52.04% | -54.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.12% | -4.54% | -36.05% | -52.04% | -54.19% |
| EBIT | -12.99% | -8.54% | -29.23% | -40.02% | -40.69% |
| EBITDA | -13.79% | -9.36% | -30.61% | -40.78% | -41.30% |
| EPS Basic | 18.29% | 22.73% | -10.89% | -51.37% | -52.28% |
| Normalized Basic EPS | 18.35% | 22.82% | -10.92% | -51.35% | -52.23% |
| EPS Diluted | 18.29% | 22.73% | -10.89% | -51.37% | -52.28% |
| Normalized Diluted EPS | 18.35% | 22.82% | -10.92% | -51.35% | -52.23% |
| Average Basic Shares Outstanding | 34.84% | 35.29% | 22.67% | 0.50% | 1.19% |
| Average Diluted Shares Outstanding | 34.84% | 35.29% | 22.67% | 0.50% | 1.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |